Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Sitagliptin

The first DPP-4 inhibitor (gliptin) approved, in 2006, for type 2 diabetes. It prolongs the action of incretins, gut hormones released after meals that stimulate insulin. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?Incretins explain a curious fact: at the same blood sugar level, glucose taken by mouth raises insulin much more than glucose given into a vein.

SitagliptinGo to the active ingredient →
SitagliptinActive ingredientSitagliptinCat. No. P-S051-001CAS 486460-32-6

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.